You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Central Nervous System Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma Trial (intensity-modulated radiotherapy (IMRT))

Not yet recruiting
  • Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
  • intensity-modulated radiotherapy (IMRT)
  • (no location specified)
Jun 4, 2023

Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)

Recruiting
  • Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
  • thiotepa combined with pomalidomide
  • Nanjing, Jiangsu, China
    Jiangsu Province People's Hospital.
Jun 27, 2023

CNS B-Cell Non-Hodgkin Lymphoma, Recurrent CNS Lymphoma, Refractory CNS Lymphoma Trial in Houston (Ibrutinib, Nivolumab)

Recruiting
  • Central Nervous System B-Cell Non-Hodgkin Lymphoma
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 13, 2022

Refractory CNS Lymphoma, Relapsed Primary CNS Lymphoma, Primary CNS Lymphoma Trial in Hangzhou (Nivolumab)

Active, not recruiting
  • Refractory Central Nervous System Lymphoma
  • +2 more
  • Hangzhou, Zhejiang, China
    Jianmin Zhang
Jul 3, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Beijing (GNC-038)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Beijing, Beijing, China
    Beijing Tiantan Hospital, Capital Medical University
Jul 31, 2022

Primary CNS Lymphoma Trial in Hangzhou (Rituximab, Lenalidomide, Methotrexate)

Completed
  • Primary Central Nervous System Lymphoma
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 18, 2022

Primary CNS Lymphoma Trial in Hanzhou (Orelabrutinib, Rituximab, Methotrexate)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Hanzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 3, 2022

Primary CNS Lymphoma Trial in Paris (Glucarpidase, Methotrexate (MTX))

Recruiting
  • Primary Central Nervous System Lymphoma
  • Paris, France
    Hôpital Pitié-Salpêtrière
Oct 24, 2022

CNS Lymphoma, Secondary CNS Lymphoma Trial run by the National Cancer Institute (NCI) (TEDD-R, TEDDI-R, Ibrutinib)

Recruiting
  • Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Primary CNS Lymphoma, Secondary CNS Lymphoma, Relapsed Cancer Trial in Miami (drug, procedure, radiation)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • +3 more
  • Miami, Florida
    Miami Cancer Institute at Baptist Health, Inc.
Dec 23, 2022

Newly-diagnosed PCNSL Treated WithMethotrexate and

Active, not recruiting
  • Primary Central Nervous System Lymphoma
  • Shanghai, China
    Department of Hematology, Huashan Hospital, Fudan University
Oct 30, 2023

Non-hodgkin Lymphoma Trial (Methotrexate, Rituximab (where available), Ibrutinib)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • (no location specified)
Aug 11, 2023

Primary CNS Lymphoma Trial in Beijing (Orelabrutinib,Rituximab and Methotrexate)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Orelabrutinib,Rituximab and Methotrexate
  • Beijing, Beijing, China
    Hospital 307
Sep 19, 2022

CNS Lymphoma Trial in Beijing (Zanubrutinib)

Recruiting
  • CNS Lymphoma
  • Beijing, Beijing, China
    Peking University People's Hospital
Aug 1, 2022

CNS Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in San Francisco (Tafasitamab, Lenalidomide)

Recruiting
  • CNS Lymphoma
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Aug 10, 2022

CNS Lymphoma Trial in Aarhus (Immunochemo)

Completed
  • Central Nervous System Lymphoma
  • Aarhus, Denmark
    Elisa Jacobsen Pulczynski
Aug 3, 2022

Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Shanghai, Shanghai, China
    Ruijin Hospital
Apr 18, 2022

Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Low-Dose Decitabine plus anti-PD-1
  • Beijing, Beijing, China
    ChinaPLAGH
Apr 18, 2023

Primary CNS Lymphoma Trial in Paris (PET-MRI)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • Paris, France
    Hôpital Pitié Salpêtrière
May 20, 2022

Primary CNS Lymphoma Trial in Zhengzhou (the dose-escalation phase)

Recruiting
  • Primary Central Nervous System Lymphoma
  • the dose-escalation phase
  • Zhengzhou, Henan, China
    Oncology Department of The First Affiliated Hospital of Zhengzho
May 30, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Saint Louis (Durvalumab, Acalabrutinib)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Mar 14, 2022

CNS Lymphoma Trial in Essen ([90Y]Y-PentixaTher)

Recruiting
  • CNS Lymphoma
  • Essen, Germany
    University Hospital Essen
Nov 16, 2023

Primary CNS Lymphoma Trial in Beijing (Camrelizumab)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Beijing, China
    Sanbo Brain Hospital Capital Medical University
Feb 10, 2022

CNS Lymphoma Trial in Nanchang (Human CD19-CD22 Targeted T Cells Injection)

Recruiting
  • Central Nervous System Lymphoma
  • Human CD19-CD22 Targeted T Cells Injection
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Dec 13, 2022

Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Methotrexate (MTX))

Recruiting
  • Primary Central Nervous System Lymphoma
  • Shanghai, Shanghai, China
    Department of Hematology, Huashan Hospital, Fudan University
Jul 26, 2022